N-acetylcysteine Plus Deferoxamine for Patients With Hypotension

Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude

Status and phase: Completed; Phase 2

Conditions: Hypotension; Acute Renal Failure

Treatments: Drug: N-acetylcysteine and deferoxamine

Study type: Interventional

Funder types: Other

Identifiers

NCT00870883

FR208621

Details and patient eligibility

About

Oxidative stress is associated with kidney damage in several different situations, including hypotension. In animal models it has been shown that the combination of n-acetylcysteine plus deferoxamine is superior to its isolate use in the treatment of several diseases. Thus the investigators aimed to determine if the administration of n-acetylcysteine plus deferoxamine could prevent renal failure in critical ill patients who develops hypotension.

Enrollment: 81 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients admitted to the ICU
• Presenting hypothesion (MAP < 60mm Hg or the needing to use vasoactive drugs) for at least 30 min in the last 12h before study inclusion

Exclusion criteria

• Age lower than 18 years old
• Chronic renal failure
• A known history of allergy to any of the study drugs
• Using n-acetylcysteine to paracetamol overdose
• Pregnant women
• Patients who used iodinated contrast medium
• Hemoglobin less than 6.5 mg/dl
• Cancer patients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

81 participants in 1 patient group

N-acetylcysteine plus deferoxamine

Experimental group

Treatment:

Drug: N-acetylcysteine and deferoxamine